From L-R: Lim In-Taek, head of health and medical policy at the Ministry of Health and Welfare; Daewoong Pharmaceutical CEO Jeon Sengho; Aditum Bio co-founder Mark Fishman; and Cha Soon-do, president of the Korea Health Industry Development Institute
April 28, 2023 11:00 AM EDT
Deals

Com­pa­ny found­ed by ex-No­var­tis ex­ecs inks $477M in-li­cense deal

Paul Schloesser

Associate Editor

Adi­tum Bio, the biotech fund launched by two for­mer No­var­tis ex­ecs, an­nounced that it formed a new com­pa­ny fo­cused on de­vel­op­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times